Clinical trials: Aggressive Behaviour
Thyroid Cancer
A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
This study plans to learn more about a drug called bexarotene for the treatment of advanced thyroid cancer. Subjects are asked to be in this study because they have thyroid cancer that will not respond to radioactive iodine…
- Trial name
- NCT00718770
- Testing
- Bexarotene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Aggression, Self-Injurious Behavior
Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control
Children with an intellectual disability often display severe destructive behavior (e.g., aggression, self-injury) that pose risks to themselves or others and represent barriers to community integration.
- Trial name
- NCT02483572
- Testing
- Functional Communication Training
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Nebraska
Diffuse Large B-cell Lymphoma, de Novo DLBCL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.
- Conditions
- Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma, Follicular Grade 3 Lymphoma
- Trial name
- PIX-R (NCT01321541)
- Testing
- Pixantrone + Rituximab, Gemcitabine + Rituximab
- Where
- 131 sites in United States, Austria and 15 more
- Volunteers
- 312 people
- Sponsor
- CTI BioPharma
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT00723099
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Fred Hutchinson Cancer Center
Hypertension
The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy
The purpose of this trial is to compare blood pressure lowering efficacy of moderate Valsartan + Amlodipine treatment regimen (160 / 5 mg) with that of aggressive regimen (320 / 10 mg) in patients uncontrolled on ARB monotherapy…
- Trial name
- EXTRA (NCT00666536)
- Testing
- valsartan and amlodipine
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- Novartis
Dementia, Aggression
Preventing Aggression in Veterans With Dementia
This study tests whether education about memory and pain might help to prevent aggression in persons with dementia who have pain.
- Conditions
- Dementia, Aggression, Pain
- Trial name
- PAVeD (NCT01325714)
- Testing
- PAVeD Intervention, Enhanced Usual Care
- Where
- United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Retinopathy of Prematurity
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
The purpose of this study was to determine the efficacy and additional advantages of intravitreal bevacizumab in the treatment of ROP for both Zone I and Zone II Posterior.
- Trial name
- BEAT-ROP (NCT00622726)
- Testing
- Bevacizumab, Conventional Laser for ROP
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- The University of Texas Health Science Center, Houston
Autism, Aggression
The Family VOICE Study
Family centered mental health treatment with children values and supports the role of parents in their child's recovery. However, medications are often the primary focus in community treatment, even in preschool age youth, with…
- Conditions
- Autism, Aggression, Bipolar Disorder, Psychotic Disorders
- Trial name
- NCT01804582
- Testing
- Family Navigator consultation
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- University of Maryland, Baltimore
Autism Spectrum Disorder, Aggression
Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism
Some individuals with autism spectrum disorders (ASD) also demonstrate irritability or aggression, which can interfere with functioning.
- Conditions
- Autism Spectrum Disorder, Aggression, Irritability
- Trial name
- NCT02552147
- Testing
- Transdermal nicotine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Yale University
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study Of The Selective PKC-β Inhibitor MS- 553
A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
- Trial name
- NCT03492125
- Testing
- MS-553, acalabrutinib, venetoclax
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- MingSight Pharmaceuticals, Inc
Anger, Aggression
Mindfulness for Anger in Veterans With PTSD
Research has consistently shown that Veterans with PTSD are more likely to experience higher levels of anger and commit aggressive acts compared to Veterans without PTSD.
- Trial name
- NCT02882802
- Testing
- Mindfulness Based Stress Reduction, Trauma Recovery Education Class
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Relapsed/Refractory Aggressive B-cell Lymphomas
Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 in participants with relapsed or refractory aggressive B-cell lymphomas who have failed 1-2 prior lines of therapy.
- Trial name
- NCT02271945
- Testing
- MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- MedImmune LLC
Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
The safety and efficacy of midostaurin (PKC412), a novel investigational drug, will be evaluated on the basis of response rate, when administered to patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL)
- Conditions
- Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)
- Trial name
- NCT00233454
- Testing
- Midostaurin
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Jason Robert Gotlib
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
This phase II trial is studying how well sorafenib works in treating patients with recurrent diffuse large B-cell non-Hodgkin's lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma
- Trial name
- NCT00131937
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Bullying
Middle School Teacher Module for a Brief Bullying Intervention Program
This study evaluates the feasibility and short-term outcomes of a teacher training designed as a companion module to a bullying bystander intervention (STAC) for middle school students in rural communities.
- Trial name
- NCT06017752
- Testing
- STAC Teacher Module
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boise State University
Desmoid Tumors, Aggressive Fibromatosis
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
Background: Desmoid tumors (also known as aggressive fibromatosis), are rare, locally invasive, slow-growing soft-tissue tumors.
- Trial name
- NCT01981551
- Testing
- PF-03084014
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated…
- Conditions
- Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Neoplasm, Mast Cell Leukemia
- Trial name
- NCT03580655
- Testing
- Avapritinib
- Where
- 32 sites in United States, Austria and 10 more
- Volunteers
- 107 people
- Sponsor
- Blueprint Medicines Corporation
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6).
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL)
- Trial name
- ZUMA-1 (NCT02348216)
- Testing
- Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 307 people
- Sponsor
- Kite, A Gilead Company
Microalbuminuria
Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria
The objective of the study is to assess the effect of standard versus aggressive inhibition of the renin-angiotensin system (RAS)in type 2 diabetic patients with microalbuminuria (MA) on; a)progression of microalbuminuria…
- Trial name
- END-IT (NCT00907374)
- Testing
- benazepril
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Charles Drew University of Medicine and Science
Dyslipidemia, Hypertension
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood…
- Trial name
- TOGETHER (NCT00412113)
- Testing
- Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 51 sites in United States
- Volunteers
- 245 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.